

Marij J P Welters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7089876/publications.pdf>

Version: 2024-02-01

58
papers

5,125
citations

159525

30
h-index

175177

52
g-index

60
all docs

60
docs citations

60
times ranked

6841
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. <i>New England Journal of Medicine</i> , 2009, 361, 1838-1847.	13.9	970
2	Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. <i>Clinical Cancer Research</i> , 2008, 14, 178-187.	3.2	346
3	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. <i>Science Translational Medicine</i> , 2014, 6, 254ra128.	5.8	325
4	Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity. <i>Clinical Cancer Research</i> , 2008, 14, 169-177.	3.2	286
5	NKG2A Blockade Potentiates CD8 ⁺ Cell Immunity Induced by Cancer Vaccines. <i>Cell</i> , 2018, 175, 1744-1755.e15.	13.5	241
6	Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11895-11899.	3.3	215
7	Association of cervical cancer with the presence of CD4 ⁺ regulatory T cells specific for human papillomavirus antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12087-12092.	3.3	201
8	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 161-169.	2.0	175
9	Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. <i>Nature Communications</i> , 2020, 11, 3083.	5.8	173
10	The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. <i>BMC Cancer</i> , 2015, 15, 652.	1.1	170
11	Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. <i>Cancer Research</i> , 2003, 63, 636-41.	0.4	166
12	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. <i>Journal of Translational Medicine</i> , 2013, 11, 88.	1.8	165
13	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1271-1286.	2.0	161
14	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. <i>Clinical Cancer Research</i> , 2016, 22, 2342-2350.	3.2	132
15	Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 634-647.	3.2	128
16	CD39 Identifies the CD4 ⁺ Tumor-Specific T-cell Population in Human Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1311-1321.	1.6	84
17	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	83
18	Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death. <i>Clinical Cancer Research</i> , 2015, 21, 781-794.	3.2	81

#	ARTICLE	IF	CITATIONS
19	A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17+ cell frequency. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 393-403.	2.0	77
20	Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. <i>International Journal of Cancer</i> , 2008, 122, 486-494.	2.3	74
21	Guidelines for the automated evaluation of Elispot assays. <i>Nature Protocols</i> , 2015, 10, 1098-1115.	5.5	74
22	Thinking Outside the Gate: Single-Cell Assessments in Multiple Dimensions. <i>Immunity</i> , 2015, 42, 591-592.	6.6	67
23	Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. <i>International Journal of Cancer</i> , 2006, 118, 950-956.	2.3	59
24	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. <i>Oncotarget</i> , 2015, 6, 32228-32243.	0.8	58
25	Addition of interferon- γ to the p53-SLP vaccine results in increased production of interferon- γ in vaccinated colorectal cancer patients: A phase I/II clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1581-1591.	2.3	50
26	Harmonization of the intracellular cytokine staining assay. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 967-978.	2.0	47
27	Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. <i>Vaccine</i> , 2007, 25, 1379-1389.	1.7	46
28	The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival. <i>Clinical Cancer Research</i> , 2019, 25, 240-252.	3.2	45
29	TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. <i>Oncotarget</i> , 2016, 7, 67087-67100.	0.8	43
30	Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response. <i>Clinical Cancer Research</i> , 2008, 14, 7188-7195.	3.2	39
31	The importance of correctly timing cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 87-103.	1.4	26
32	CD163 ⁺ cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer. , 2020, 8, e001053.		26
33	The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1953-1963.	2.0	23
34	Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer. <i>Onc Immunology</i> , 2016, 5, e1255393.	2.1	22
35	EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer. <i>PLoS ONE</i> , 2018, 13, e0203402.	1.1	22
36	Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1451-1463.	2.0	21

#	ARTICLE	IF	CITATIONS
37	T-regulatory cells in tumour-specific vaccination strategies. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1365-1379.	1.4	17
38	Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative. <i>Journal of Translational Medicine</i> , 2015, 13, 370.	1.8	17
39	HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1163-1173.	2.0	17
40	CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors. , 2022, 10, e003995.		16
41	Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival. , 2022, 10, e004346.		15
42	Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls. <i>Vaccine</i> , 2019, 37, 7280-7288.	1.7	14
43	The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 545385.	1.3	14
44	Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. <i>Vaccine</i> , 2004, 23, 305-311.	1.7	13
45	Mesenchymal Stromal Cell Therapy Is Associated With Increased Adenovirus-Associated but Not Cytomegalovirus-Associated Mortality in Children With Severe Acute Graft-Versus-Host Disease. <i>Stem Cells Translational Medicine</i> , 2014, 3, 899-910.	1.6	12
46	Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers. <i>Frontiers in Immunology</i> , 2020, 11, 576756.	2.2	12
47	Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 6366.	1.7	10
48	A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3113-TPS3113.	0.8	9
49	PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. <i>Cancers</i> , 2021, 13, 5179.	1.7	7
50	Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5525-5525.	0.8	6
51	Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance. <i>Journal of Immunological Methods</i> , 2018, 458, 74-82.	0.6	5
52	Interferon- γ and IL -5 associated cell-mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa. <i>Clinical and Experimental Dental Research</i> , 2021, 7, 903-913.	0.8	5
53	Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. , 2020, 8, e001607.		4
54	Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 140-140.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Prediction the clinical outcomes of cancer patients after peptide vaccination.. Journal of Clinical Oncology, 2019, 37, e14295-e14295.	0.8	4
56	T and NK Cells in IL2RG-Deficient Patient 50 Years After Hematopoietic Stem Cell Transplantation. Journal of Clinical Immunology, 2022, 42, 1205-1222.	2.0	2
57	Optimization in Detection of Antigenâ€Specific T Cells Through Differentially Labeled MHC Multimers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 955-964.	1.1	0
58	35â€Chemokine-driven spatial organization of immune cell microaggregates marks oropharyngeal squamous cell carcinomas containing tumor-specific T cells. , 2021, 9, A41-A41.		0